作者:Daniel L. Priebbenow、Mitch Mathiew、Da-Hua Shi、Jitendra R. Harjani、Julia G. Beveridge、Marina Chavchich、Michael D. Edstein、Sandra Duffy、Vicky M. Avery、Robert T. Jacobs、Stephen Brand、David M. Shackleford、Wen Wang、Longjin Zhong、Given Lee、Erin Tay、Helena Barker、Elly Crighton、Karen L. White、Susan A. Charman、Amanda De Paoli、Darren J. Creek、Jonathan B. Baell
DOI:10.1021/acs.jmedchem.1c00044
日期:2021.4.8
potent in vitro activity against Plasmodium falciparum parasites were recently discovered. To improve the pharmacokinetic properties of the triazine derivatives, a new structure–activity relationship (SAR) investigation was initiated with a focus on enhancing the metabolic stability of lead compounds. These efforts led to the identification of second-generation highly potent antimalarial bis-triazines
最近发现了新型 3,3'-二取代-5,5'-双(1,2,4-三嗪)化合物,具有有效的体外抗恶性疟原虫寄生虫的活性。为了改善三嗪衍生物的药代动力学特性,启动了一项新的构效关系(SAR)研究,重点是增强先导化合物的代谢稳定性。这些努力导致了第二代高效抗疟药双三嗪的鉴定,以三嗪23为例,其体外代谢稳定性显着改善(人和小鼠肝微粒体中的蛋白质为 8 和 42 μL/min/mg)。在 Peters 4 天试验中,还观察到二取代三嗪二聚体23可以抑制寄生虫血症,平均 ED 50值为 1.85 mg/kg/天,并表现出快速杀灭特性,揭示了一类新型口服抗疟化合物兴趣。